Dr. Syage has over 30 years of experience in creating and leading the development of innovative technologies in medical and analytical instrumentation. He is regarded as a leading expert in mass spectrometry and trace chemical detection.
Dr. Syage served as CEO and Co-Founder of ImmunogenX, a global leader in the development of treatments for celiac disease, which developed latiglutenase before its combination with Entero Therapeutics (formerly First Wave BioPharma). Previously he founded Syagen Technology, Inc. and as CEO led its growth culminating in its successful acquisition by French multinational Safran S.A. in 2011. Dr. Syage is an investor and co-founder of several other companies and currently sits on the Board of Directors of Advanced Telesensors, PhageTech, Analytical Detection (Chairman), and Appellation Ventures (Chairman). He has published over 140 papers, delivered about 100 invited talks, has over 30 U.S. patents issued or pending, and appears on the list of the Most Highly Cited Chemists.
His honorary positions include Fellow of the American Physical Society, Visiting Professor at UC Irvine, Visiting Professor at the Université de Paris-Sud, Editorial Board member of the Journal of Physical Chemistry, and invitee to the Nobel Symposium in Chemistry. He has received a Tibbets Award (SBIR) and was recently inducted into the Orange County OC 500 Directory of Influence. He received BA and PhD degrees from Hamilton College and Brown University, respectively, where he won several academic awards including Best Thesis. He was a postdoctoral fellow at Caltech under Nobel Laureate Ahmed Zewail.
